Close Menu

NEW YORK (GenomeWeb) – The New York Genome Center said today that it has received $6 million in funding for its Center for Genomics of Neurodegenerative Disease (CGND) from two foundations.

The ALS Association is committing $3.5 million to the CGND, including a $1 million commitment from its Greater New York chapter. In addition, the Tow Foundation is contributing $2.5 million.

Previously, following the 2014 Ice Bucket Challenge, the ALS Association gave $2.5 million to the CGND to match a $2.5 million gift from the Tow Foundation.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.